Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Merck Serono Hands Parkinson Disease Drug Safinamide Back to Newron

Firm says decision results from pipeline review, and belief that safinamide has more limited market potential than originally envisaged.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Myriad Genetics Trial: Your Thoughts?

Do you agree with the Supreme Court’s decision in the Myriad case?

Suggest a Poll